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Abstract
Over the past decade, cell therapies have provided promising strategies for the treatment of ischaemic cardiomyopathy. Particularly, the benefi-
cial effects of stem cells, including bone marrow stem cells (BMSCs), endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs),
embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), have been demonstrated by substantial preclinical and clinical stud-
ies. Nevertheless stem cell therapy is not always safe and effective. Hence, there is an urgent need for alternative sources of cells to promote
cardiac regeneration. Human villous trophoblasts (HVTs) play key roles in embryonic implantation and placentation. In this study, we show that
HVTs can promote tube formation of human umbilical vein endothelial cells (HUVECs) on Matrigel and enhance the resistance of neonatal rat
cardiomyocytes (NRCMs) to oxidative stress in vitro. Delivery of HVTs to ischaemic area of heart preserved cardiac function and reduced fibro-
sis in a mouse model of acute myocardial infarction (AMI). Histological analysis revealed that transplantation of HVTs promoted angiogenesis
in AMI mouse hearts. In addition, our data indicate that HVTs exert their therapeutic benefit through paracrine mechanisms. Meanwhile, injec-
tion of HVTs to mouse hearts did not elicit severe immune response. Taken together, our study demonstrates HVT may be used as a source for
cell therapy or a tool to study cell-derived soluble factors for AMI treatment.
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Introduction
AMI, also known as heart attack, leads to loss of cardiomyocytes,
scar formation, ventricular remodelling and subsequent incurable
heart failure [1, 2]. Despite great advances in pharmacological and
invasive treatment regimens, AMI causes high mortality and morbid-
ity worldwide [3].
Cell-based therapies offer a promising option for the
treatment of AMI [4]. And the beneficial effects of various cell
types in AMI have been demonstrated by basic researches and
clinical studies, which include skeletal myoblasts, BMSCs, EPCs,
MSCs, ESCs, iPSCs, cardiac stem cells (CSCs) and cardiospheres
[4–13].
Stem cell therapy, however, is not always safe and effective
[14]. For example, transplantation of skeletal myoblasts in injured
hearts can lead to severe arrhythmia which limits the further inves-
tigation of this cell type [15]. Intramyocardial injection of pluripo-
tent stem cells such as ESCs and iPSCs can lead to tumorigenicity
and immunogenicity [16, 17]. On the other hand, BMSC therapy is
generally safe but recent meta-analysis has revealed that the
*Correspondence to: Ke CHENG, Ph.D.
E-mail: ke_cheng@suda.edu.cn
Qingyu WU, M.D., Ph.D.
E-mail: wuqy@suda.edu.cn
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
doi: 10.1111/jcmm.13165
J. Cell. Mol. Med. Vol 21, No 10, 2017 pp. 2432-2440
benefits of such therapy for AMI are only marginal [18]. Intrinsic
heart stem cells were identified one and half decades ago and such
research has propelled the recent clinical trials using ckit-positive
CSCs or cardiosphere cells [11, 19]. However, ckit-positive cells
are rare in the heart and the expansions of CSCs and cardiosphere
cells are time-consuming.
In consideration of all this, it is imperative to seek for new cell
types to promote cardiac regeneration. Placental trophoblasts play
pivotal roles at the maternal and foetal interface that is essential for
nutrient and oxygen transfer [20]. Trophoblasts can secrete a wide
range of angiogenic factors and cytokines, such as vascular endothe-
lial growth factor (VEGF) and insulin-like growth factor (IGF) [21, 22].
These factors have been reported to play essential roles in heart
regeneration [23]. Moreover, trophoblasts can produce Fas ligand to
induces immune cell apoptosis [24]. Furthermore, the expression of
FSTL1 was also detected in primary term human villous [25]. It is
intriguing that the recombinant bacterial-synthetized human Fstl1 pro-
tein promotes myocardial repair and regeneration by stimulating pre-
existing cardiomyocytes to re-enter into cell cycle entry and division
[26–28]. In addition, human trophoblast injection did not cause
tumour formation in nude mice [29].
Hence, we suggested that HVTs could secrete pro-angiogenic and
pro-cardiogenic growth factors to promote heart regeneration after
AMI. The data presented here provide new insights into the mecha-
nisms of HVT regenerative biology and also form the foundation of
future development of HVT-based therapy for MI treatment.
Materials and methods
HVT culture and paracrine assay
HVTs (ScienCell Research Laboratories, San Diego, CA, USA) were
maintained with trophoblast medium (ScienCell Research Laboratories)
plus 5% FBS, 1% trophoblast growth supplement and 1% penicillin/
streptomycin solution under 5% CO2 at 37°C, as described previously
[30]. When the cells reached 90% confluence, the culture medium was
changed to serum-free IMDM for 3 days for conditioning. Then, the
conditioned medium (CM) from HVTs was harvested. Meanwhile,
5 9 105 NRCMs isolated from 48-hrs-old Sprague Dawley rat pups
[12] were plated onto fibronectin-coated 12-well plates (Corning, New
York, USA) with 1 ml IMDM (Gibco, Waltham, MA, USA) containing
Fig. 1 Characterization of HVTs. (A) Morphology of HVTs in trophoblast medium (TM) after 24 hrs. (B) Transcription of RNAs by RT-PCR in HVTs.
(C, D) Protein expression of HVTs by immunofluorescence or Western blotting. HEK293 cell lysate is a positive control in D.
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20% FBS (Hyclone, Logan, UT, USA) for 48 hrs. Then NRCMs were
incubated with HVT-derived CM, and plain IMDM as the control and
injured with 100 lM H2O2. After 24 hrs, cells were fixed with 4% PFA
and apoptotic cells were detected by terminal deoxynucleotidyl trans-
ferase dUTP nickend labelling (TUNEL) assay using the In Situ Cell
Death Detection Kit (Roche Diagnostics, Indianapolis, IN, USA).
The pro-angiogenic effects of HVT-CM were studied in an endothelial
cell tube formation assay. HUVECs; from ATCC were seeded onto
growth factor-reduced MatrigelTM (BD Biosciences, New York, USA) in
96-well plates at a density of 2 9 104 cells per well. 100 ll HVT-CM or
DMEM (as control) was added into the wells. Within 6 hrs, the wells
were imaged with a Leica (Wetzlar, Germany) white light microscope.
The average tube length was then measured with NIH Image J Software
(NIH, Bethesda, MD, USA).
The presence of various proteins in the CM was assayed with a
human angiogenesis antibody array (RayBiotech, Norcross, GA, USA).
RT-PCR
Total RNA was extracted from HVT cell pellets using a High Pure RNA
Isolation Kit (OMEGA bio-tek, Norcross, GA, USA), according to the
manufacturer’s instructions. The first strand of cDNA synthesis from
RNA template was performed with cDNA reverse transcription kit
(Thermo, Logan, UT, USA), according to manufacturer’s instructions.
The sequences of the primers used in this study were listed as follows:
for a-hCG, forward primer AACCCATTCTTCTCCCAGCC, reverse primer
GCCGTGTGGTTCTCCACTTT; for b-hCG, forward primer ATGTGCGCTTC-
GAGTCCATC, reverse primer GGGCCTTTGAGGAAGAGGAG; for angio-
genin, forward primer CCTGACCTCACCCTGCAAAG, reverse primer GCT
CGGTACTGGCATGGAG; for CXCR4, forward primer TCATCACGCTTCCC
TTCTGG, reverse primer CCACCTTTTCAGCCAACAGC.
Animal procedures
All animal experiments were performed in accordance with the experi-
mental protocol approved by Soochow University Laboratory Animal
Center. The AMI model was performed as described before [31]. Briefly,
male C57BL6 mice were anaesthetized with 3% isoflurane inhalation. A
small skin cut and a purse suture were made over the left thoracic wall.
After that, a small incision was made at the fourth intercostal space.
The heart was then gently popped out through the window. The left
main descending coronary artery (LCA) was ligated at a site 3 mm from
its origin. After the ligation, one million of HVTs were intramyocardially
injected into the border zone of the mice immediately. Then the heart
was placed back into the intrathoracic space with fast air evacuation
and chest wall closure, by the previously placed purse-string suture. All
animals received buprenorphine for analgesia after the surgery.
Echocardiography
Mice were anaesthetized with a 1.5% isoflurane–oxygen mixture at
baseline (4 hrs post-MI) and 4 weeks afterwards. And two-dimensional
short axis images were recorded using Vevo2100 System (Visual Son-
ics, Toronto, ON, Canada).
Tissue harvesting
Mice were killed at various time-points (24 hrs for TUNEL staining,
7 days for CD8 staining and 28 days for histology) after treatment, and
then the hearts were harvested and snap-frozen in optimal cutting tem-
perature (OCT) compound (Leica) at 30°C for cryosectioning and his-
tology or immersed to liquid nitrogen for Western blotting.
Western blotting
Heart tissues stored in liquid nitrogen were lysed using RIPA buffer
(Beyotime, Nantong, Jiangsu, China). Protein concentrations were mea-
sured by the BCA method (Thermo). To separate proteins, equal
amounts of protein samples were loaded to SDS-PAGE gels, separated
and then transferred onto PVDF membranes (Millipore, Billerica, MA,
USA). Then the membranes were incubated with primary antibodies
against VEGF, hepatocyte growth factor (HGF), insulin-like growth fac-
tor-1 (IGF1) and GAPDH, respectively. This was followed by blotting
with HRP-conjugated secondary antibodies. Immunoreactive bands were
visualized by enhanced chemiluminescence on exposed X-ray films.
Masson’s trichrome staining
Masson’s trichrome stain was performed as described [32]. In brief,
sections were immersed in Bouin’s solution overnight. Slides were then
rinsed for 10 min. under running water to remove excessive picric acid.
Then the slides were transferred to Weigert’s haematoxylin solution for
5 min. Slides were then rinsed and stained with scarlet-acid fuchsin for
5 min. and rinsed again. Slides were then stained with phospho-
tungstic/phosphomolybdic for 10 min. and transferred directly into ani-
line blue solution for 5 min., and 2% acetic acid for 2 min. each. Slides
were then rinsed, dried, and mounted using DPX mounting media.
Histology
Hearts were sectioned at a thickness of 3 lm for immunofluorescence stain-
ing. The sections were first blocked with 5% BSA in PBS and then stained with
Fig. 2 Paracrine assays, HUVEC tube formation and NRCM apoptosis in HVT-CM. (A) Representative antibody array images showing the proteins
present in HVT-CM and control TM. Abbreviations: CM, conditioned media; TM: trophoblast medium; CXCL5, C-X-C motif chemokine 5; GRO:
growth-regulated protein; IL8: interleukin-8; CCL2: C-C motif chemokine 2; TIMP-1: Metalloproteinase inhibitor 1; TIMP-2: Metalloproteinase inhi-
bitor 2; ANGPT-1: Angiopoietin-1; ANFPT-: Angiopoietin-2; MMP-1: Interstitial collagenase; uPAR: Urokinase plasminogen activator surface recep-
tor. (B) Representative tube formation by HUVECs on Matrigel incubated with HVT-CM or control DMEM (n = 12–14). (C) Representative
confocal images showing NRCMs exposed to 100 lM H2O2 for 24 hrs in HVT-CM or control IMDM. Apoptotic cells were detected by TUNEL
staining and quantified (n = 5). ***indicates P<0.001 when HVT group compared to PBS. Data are presented as mean  S.D.
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anti-von Willebrand factor (Abcam Cambridge, MA, USA), anti-human nuclei
antigen (Millipore) and CD8 (Bio-Rad, Hercules, CA, USA) antibodies. DyLight
488- or 594-conjugated secondary antibodies (Immunoreagents, NC, Raleigh,
NC, USA) were used in conjunction with these primary antibodies. Images
were taken by a Zeiss (Olympus, Tokyo, Japan) confocal microscopy system.
Apoptotic cells in heart tissues were detected by In Situ Cell Apoptosis Detec-
tion Kit, FITC (Sangon, Shanghai, China).
Statistical analysis
Results are presented as mean  standard deviation (S.D.). Compar-
isons between PBS and HVT groups were performed with two-tailed
unpaired Student’s t-test. Differences were considered statistically sig-
nificant when P < 0.05.
Results
Characterization of human HVTs
To confirm the identity of human HVTs, the RNA and protein expres-
sions of widely accepted HVT markers were examined. As indicated in
Figure 1A, HVT cells exhibited a typical multiangular morphology as
descriptions by Graham et al. [33] under our culture conditions.
Expressions of a/b-hCG, CXCR4 and angiogenin were detected by RT-
PCR (Fig. 1B). Meanwhile, immunocytochemical staining confirmed
the a/b-hCG expression in HVTs (Fig. 1C). Moreover, VEGF, HGF and
IGF-1 proteins were detected in HVT cell lysates (Fig. 1D) by Western
blotting. These compound data sets confirmed the identity of HVTs.
Paracrine assays on HVTs
A cytokine array (Fig. 2A) revealed that HVTs secreted pro-angiogenic
factors such as angiogenin, angiopoietin-1 (ANGPT1), angiopoietin-2
(ANGPT2) and metalloproteinase inhibitor-1/2 (TIMP-1/2). Given the
presence of the pro-angiogenic growth factors in HVT cell lysates
(Fig. 1D) and the result of paracrine assays of HVT-derived CM, we
showed that CM from HVTs could promote tube formation of endothelial
cells in vitro. When incubated with HVT-CM, the tube formation of
HUVECs on MatrigelTM was enhanced within 6 hrs (Fig. 2B), as com-
pared to the tubes formed in control DMEM. Furthermore, HVT-CM
enhanced the resistance of NRCMs to oxidative stress. After exposure to
100 lM H2O2 for 24 hrs, the number of TUNEL-positive cells was lower
in the HVT-CM group than that in the control IMDM group (Fig. 2C).
Intramyocardial injection of HVTs improves
cardiac function and decreases infarct size
The animal study design is outlined in Figure 3A. To determine the
cardiac function, echocardiography was performed at 4 hrs
(baseline) and 28 days post-MI (Fig. 3A). Heart morphometry at
4 weeks showed HVT injection reduced left ventricular (LV) cham-
ber dilation as compared to PBS-treated mice (Fig. 3B). The data
indicated that HVT treatment protected cardiac functions while the
cardiac functions in PBS-treated mice continued to deteriorate
(Fig. 3C). We reasoned that part of HVT therapeutic effects on car-
diac function may come from decreased scar size. Thus, fibrosis
was analysed by Masson’s trichrome staining. Compared to PBS-
injected hearts, HVT treatment significantly inhibited scar formation
(Fig. 3D). These data conferred the therapeutic benefits of HVTs in
our mouse models of AMI.
HVTs attenuate tissue apoptosis and promote
angiogenesis
To test the cardioprotective effects of HVTs, we performed TUNEL
staining to evaluate myocardial apoptosis 24 hrs after the treatment.
HVT injection reduced TUNEL-positive nuclei (Figs. 4A and B). These
data sets manifest a cardioprotective effect of HVT treatment post-MI.
As CM from HVTs promoted the tube formation of HUVECs
in vitro (Fig. 2A), we showed that transplantation of HVTs can stimu-
late neovascularization in post-MI hearts. vWF-positive capillary den-
sity was strikingly higher in the HVT-treated group than that in the
PBS control-treated group (Figs. 4C and D).
HVTs do not graft permanently or trigger
immune reactions in the mouse heart
Although a few HNA+ cells could be detected in the cell-injected hearts
(Fig. 5A), the small numbers of engrafted cells seemed not sufficient
to support the observed therapeutic benefits. This suggested that
HVTs exerted cardiac protection through paracrine effects rather than
direct engraftment and differentiation [34].
To evaluate the immunogenicity of such xenogenic transplantation
of HVTs [35], immunofluorescent staining of immune cells was per-
formed 7 days after cell injection. The numbers of CD8-positive T
cells were indistinguishable between the HVT and PBS treatment
groups (Fig. 5B and C), suggesting that injection of human HVTs did
not trigger T-cell infiltration in the mouse heart.
Discussion
Cardiovascular disease (CVD) especially MI is the major cause of
morbidity and mortality worldwide [3]. The ischaemia often results in
irreversible cardiomyocyte death, which further translates into inflam-
mation, fibrosis and deterioration of cardiac function, and ultimately
leads to heart failure [36]. Despite tremendous advances in modern
medical therapy, the prognosis for heart failure patients remains
unsatisfactory. Every year there are still a substantial number of
2436 ª 2017 The Authors.
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Fig. 3 Cardiac function and fibrosis. (A) Schematic diagram showing the animal procedures. (B) Representative echocardiography images at 4 weeks
after treatment. The pericardium and endocardium are outlined with yellow and red dotted lines, respectively. LVVd, left ventricular volume in dias-
tole; LVVs, left ventricular volume in systole. (C) Left ventricular ejection fraction (LVEF) measured by echocardiography at baseline (left) and
4 weeks afterwards (right) in PBS or HVT groups (n = 7–9 mice per group). Baseline LVEFs were indistinguishable between the two groups. (D)
Representative Masson’s trichrome-stained images and quantification of fibrotic area of the infarcted myocardium 4 weeks after treatments (n = 4
mice per group). Scar tissue and viable myocardium are identified by the blue and red colours, respectively. Snapshots of the infarct border zone
(black box area) are presented beneath each group. **indicates P<0.01 when HVT group compared to PBS., ***indicates P<0.001 when HVT group
compared to PBS. Data are presented as mean  S.D.
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Fig. 4 Reduced apoptosis and increased angiogenesis. (A) Microscopy images of TUNEL staining in heart sections of HVT- or PBS-treated mice 8 hrs
after MI. Apoptotic cells (red colour) are highlighted with white arrowheads. (B) Quantitation of apoptotic cells (n = 4). (C) Representative micrographs
showing vWF-stained vasculatures in the PBS and HVT groups 4 weeks after treatment. (D) Quantification of vWF-stained vasculatures (n = 3 mice per
group). ***indicates P<0.001 when HVT group compared to PBS. Data are presented as mean  S.D.
Fig. 5 Cell retention and immune response in heart tissues. (A) Representative confocal images showing the cell retention of HVTs (positive for
human nuclei antigen (HNA); green, indicated by white arrows) in the infarct border zone. (B) Representative confocal images showing CD8-positive
cells in the infarct border zone. (C) Quantification of CD8-positive cells in the infarct border zone. ns indicated there was no significant difference
when HVT group compared to PBS. Data are presented as mean  S.D.
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patients suffering from progressive heart failure as a result of myo-
cardium injury.
The last decade witnessed a burst of cell therapy trials for heart
diseases. Various sources of cells were studied to treat MI. These
cells include telocytes, skeletal myoblasts, BMSCs, EPCs, MSCs,
ESCs and iPSCs [1, 37, 38]. Intrinsic heart stem cells in MI treatment
research have propelled the recent clinical trials using ckit-positive
CSCs or cardiosphere-derived cells [11, 19].
Nevertheless, there is an urgent need for alternative cells sources
to promote cardiac regeneration. HVTs can be readily isolated from
human placental villous. Comparing to stem cells, HVTs can be readily
grown into a large quantity, avoiding ethical and logistical issues as
harvesting of HVTs does not harm the mother or the infant. Overall,
the HVTs encompass several properties, as described above, which
encourage their utilization in the cell transplantation for cardiac repair.
Our present results demonstrated that HVTs are capable of pro-
moting angiogenesis, reducing apoptosis and fibrosis, and improving
cardiac function in mice with AMI.
We found that CM collected from HVTs can promote the tube for-
mation of HUVECs on MatrigelTM and enhance the resistance of rat
cardiomyocytes to oxidative stress in vitro. After injection, only a few
of HVTs engrafted in the mouse heart. This might indicate that
injected cells contributed to therapeutic benefits mainly through para-
crine effects, for example secretion of regenerative factors. It has
been reported that trophoblasts produce various factors including
VEGF, SDF-1, HGF and IGF-1 [39]. These factors have been shown to
play essential roles in heart regeneration. VEGF is a pro-angiogenic
agent [40]. SDF-1 augments EPCs recruitment and haematopoietic
stem cells (HSCs) mobilization and homing to ischaemic sites, subse-
quent promoting neovascularization in infarct area [41, 42]. HGF has
mitogenic, morphogenic, and anti-apoptotic effects and plays pivotal
roles in regeneration and protection of organs such as liver, kidney
and lung and reduces ischaemia/reperfusion injury in AMI hearts
directly by suppressing cardiomyocyte cell death [43], and IGF-1 is a
potent pro-survival factor, which has been shown to reduce myocyte
apoptosis and ventricular dilation after infarction [44]. In addition, it
has been reported that genes related to apoptosis inhibition were up-
regulated in first trimester placental villi [45], which may contribute to
cardiomyocyte survival after ischaemia.
Xenogenic/allogeneic cell transplantation can lead to potential
graft-versus-host disease [35]. Here we showed that there were no
significant differences in the numbers of CD8-positive T cells between
the HVT and PBS treatment groups in immunocompetent (normal)
mice. This is consistent with the previous observations regarding the
immunomodulatory effects of HVTs. During pregnancy, to prevent
deleterious immune response towards the conceptus, trophoblasts
induce tolerance of the foetal allograft against maternal immune sys-
tem through Fas–FasL interactions [46, 47].
Conclusion
Taken together, this study demonstrates the regenerative potential
of HVTs in AMI. Such therapeutic benefits are mediated by the
pro-angiogenic, anti-apoptotic and anti-fibrotic effects of HVTs.
Therefore, HVTs may be used an alternative cell source for the
treatment of MI.
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